Status:
COMPLETED
A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess levels in blood plasma of BMS-986278 and the food effect in healthy participants.
Eligibility Criteria
Inclusion
- Healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations in the opinion of the investigator
- Women and men must agree to follow specific methods of contraception
Exclusion
- Women of childbearing potential (WOCBP) and Women who are pregnant or breastfeeding
- Any significant acute or chronic medical condition that presents a potential risk to the participant and/or that may compromise the objectives of the study
- Exposure to any investigational drug or placebo within 4 weeks of first study treatment administration.
- History of any significant drug and/or food allergies (such as anaphylaxis or hepatotoxicity)
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
July 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 7 2020
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04468815
Start Date
July 10 2020
End Date
October 7 2020
Last Update
May 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICON (LPRA) - Salt Lake
Salt Lake City, Utah, United States, 84124